Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.62 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.62 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129417 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18746352 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL10070674 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18746353 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18387240 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18383020 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL10298049 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL16900305 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18387241 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL13895786 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181607-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | The University of the Regents of California (US) | 2023-06-15 | — | — | US | disclosed |
| US-11179474-B1 | Nanoparticle-based liver-targeting therapy and imaging | MIDATECH LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-10688125-B2 | Nanoparticles and their use in cancer therapy | MIDATECH LTD. (GB) | 2020-06-23 | — | — | US | disclosed |
| WO-2020120785-A1 | ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE | MIDATECH LTD (GB) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020120787-A1 | NANOPARTICLE-BASED THERAPY OF INFLAMMATORY DISORDERS | MIDATECH LTD (GB) | 2020-06-18 | — | — | WO | disclosed |
| EP-3217958-B1 | SUSTAINED RELEASE ENCAPSULATED NANOPARTICLES | MIDATECH LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| US-10443026-B2 | Polygonal scaffold and manufacturing method thereof, and protein modulator and manufacturing method thereof | NATIONAL TSING HUA UNIVERSITY (TW) | 2019-10-15 | — | — | US | disclosed |
| US-20190194590-A1 | POLYGONAL SCAFFOLD AND MANUFACTURING METHOD THEREOF, AND PROTEIN MODULATOR AND MANUFACTURING METHOD THEREOF | NATIONAL TSING HUA UNIVERSITY (TW) | 2019-06-27 | — | — | US | disclosed |
| EP-2579898-B1 | PEPTIDE-CARRYING NANOPARTICLES | MIDATECH LTD (GB) | 2019-01-09 | — | — | EP | disclosed |
| EP-2717858-B1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | AQUESTIVE THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20120301535-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | AQUESTIVE THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120301535-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | AQUESTIVE THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | MIDATECH PHARMA PLC (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | MIDATECH PHARMA PLC (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120070382-A1 | FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF | MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070382-A1 | FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF | MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120009260-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | AQUESTIVE THERAPEUTICS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120009260-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | AQUESTIVE THERAPEUTICS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20090181101-A1 | NANOPARTICLES COMPRISING ANTIBACTERIAL LIGANDS | MIDATECH PHARMA PLC (GB) | 2009-07-16 | — | — | US | disclosed |
| WO-2007015105-A2 | NANOPARTICLES COMPRISING ANTIBACTERIAL LIGANDS | RADEMACHER THOMAS WILLIAM (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194590-A1 | POLYGONAL SCAFFOLD AND MANUFACTURING METHOD THEREOF, AND PROTEIN MODULATOR AND MANUFACTURING METHOD THEREOF | PPIA, PPIH, FKBP1A | LGALS8 3873/4885LGALS3 3789/4885LGALS4 3712/4885 |
| US-10688125-B2 | Nanoparticles and their use in cancer therapy | EPCAM, CLTA, CORO1A | LGALS8 85/4885LGALS3 11/4885LGALS4 36/4885 |
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | CALCA, LNPEP, CLTA | LGALS8 160/4885LGALS3 99/4885LGALS4 134/4885 |
| US-10443026-B2 | Polygonal scaffold and manufacturing method thereof, and protein modulator and manufacturing method thereof | PPIA, PPIH, FKBP1A | LGALS8 4198/4885LGALS3 4072/4885LGALS4 4064/4885 |
| US-11179474-B1 | Nanoparticle-based liver-targeting therapy and imaging | LGALS1, CA14, CD44 | LGALS8 27/4885LGALS3 6/4885LGALS4 9/4885 |
| US-20090181101-A1 | NANOPARTICLES COMPRISING ANTIBACTERIAL LIGANDS | CD63, CLTB, LGALS3BP | LGALS8 37/4885LGALS3 11/4885LGALS4 38/4885 |
| US-20120009260-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | CD63, DSTN, EPCAM | LGALS8 878/4885LGALS3 369/4885LGALS4 1202/4885 |
| US-20120301535-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | CALCA, LNPEP, IAPP | LGALS8 260/4885LGALS3 156/4885LGALS4 196/4885 |
| US-20230181607-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | TMPRSS4, ACE, ACE2 | LGALS8 33/4885LGALS3 43/4885LGALS4 27/4885 |
| US-20120070382-A1 | FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF | TLR3, TLR5, PARP15 | LGALS8 1606/4885LGALS3 399/4885LGALS4 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.